NewcelX Files Pre‑IND for NCEL‑101, Pioneering Type 1 Diabetes Therapy
NewcelX Ltd. files Pre‑IND for NCEL‑101, a novel type 1 diabetes therapy, marking a major step toward clinical trials and expanding its biopharma portfolio.
2 minutes to read
NewcelX Ltd